AB SCIEX, a global leader in analytical technologies, today introduced the AB SCIEX API 3200MD™ and 3200MD QTRAP LC/MS/MS systems*, two devices that can be used to analyze trace levels of multiple compounds in human samples for diagnostic purposes.
Mass spectrometry is an analytical technology that has the potential to improve the quality of results for use in clinical diagnostics, while reducing costs compared to other technologies.
BD Diagnostics, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for nasopharyngeal wash, aspirate and swab in transport media specimens on the BD Veritor System for Rapid Detection of respiratory syncytial virus (RSV). This new product is cleared for use in clinical settings.
med fusion and Theranostics Health have entered into a Market Development Agreement to validate the clinical utility of Theranostics' TheraLink Assays for use in patients with malignant diseases. The goal of this relationship is to help accelerate advancement of new methods in molecular diagnostics testing and their use in personalized predictive treatments.